Crohn's Disease (CD) Archives - Medical Conferences

Therapeutic antibody clearance reliable predictor for endoscopic outcomes in CD

Presented By

Dr Erwin Dreesen, KU Leuven, Belgium

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 11:46

TL1A-LTB axis induces perianal fistulising disease-associated changes in CD

Presented By

Dr Victoria Gudino, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Spain

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 11:31

Emulsifier-restrictive diet effective in alleviating symptoms in CD

Presented By

Dr Aaron Bancil, King’s College London, UK

Trial

ADDapt

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 11:26

Could stem cell transplantation be a fruitful solution for refractory CD?

Presented By

Dr Louis Cohen, Icahn School of Medicine at Mount Sinai, NY, USA

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 11:24

Positive results for TL1A inhibitor duvakitug in CD

Presented By

Prof. Vipul Jairath, Western University, Canada

Trial

Phase 2, RELIEVE UCCD

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 10:52

Improving efficacy with longer mirikizumab treatment in CD

Presented By

Prof. Séverine Vermeire, KU Leuven, Belgium

Trial

Phase 3, VIVID-2

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 10:39

Latest data for subcutaneous guselkumab in CD and UC

Presented By

Prof. Ailsa Hart, London North-West University, UK; Prof. Laurent Peyrin-Biroulet, University of Lorraine, France

Trial

Phase 3, GRAVITI, ASTRO

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 10:31

VEDOKIDS: Long-term outcomes of vedolizumab in paediatric IBD

Presented By

Dr Ohad Atia, Shaare Zedek Medical Centre, Israel

Trial

VEDOKIDS

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 09:56

PREdiCCT: Role of psychosocial factors in IBD flares unravelled

Presented By

Dr Lauranne Derikx, Erasmus MC, the Netherlands

Trial

PREdiCCT

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 09:49

ECCO consensus on diet and nutrition in IBD

Presented By

Dr Richard Hansen, University of Dundee, UK; Dr Vaios Svolos, University of Thessaly, Greece

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 09:20

A paradigm shift in CD clinical practice

Presented By

Dr Nuru Noor, University of Cambridge, UK

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:24

LOVE-CD: Vedolizumab yields better outcomes in early than in late CD

Presented By

Prof. Geert D’Haens, Amsterdam UMC, the Netherlands

Trial

LOVE-CD

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:24

Moving towards the prevention of IBD

Presented By

Dr Arno Bourgonje, University Medical Center Groningen, the Netherlands

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:23

New insights into perianal fistulising CD pathogenesis may lead to new therapies

Presented By

Dr Siyan Cao, Washington University, USA

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:23

Risankizumab influences key pathogenic Th17 cells in CD

Presented By

Dr Daniele Noviello, University of Milan, Italy

Trial

SEQUENCE

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:23

CULTIVATE: Promising signal for etrasimod in Crohn’s disease

Presented By

Prof. Geert D’Haens, Amsterdam UMC, the Netherlands

Trial

Phase 2, CULTIVATE

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:22

GALAXI 2 & 3: Guselkumab proves efficacy in Crohn’s disease

Presented By

Dr Remo Panaccione, University of Calgary, Canada

Trial

GALAXI

Conference

DDW 2024

Type

Peer-reviewed article

11 July 2024 13:01

VEDOKIDS: Vedolizumab maintains remission in patients with paediatric IBD

Presented By

Dr Ronen Stein, Children's Hospital of Philadelphia, USA

Trial

VEDOKIDS

Conference

DDW 2024

Type

Peer-reviewed article

11 July 2024 12:54

ADMIRE-CD II: Darvadstrocel does not meet primary endpoint in complex Crohn’s perianal fistulas

Presented By

Dr Laura Raffals, Mayo Clinic, USA

Trial

Phase 3, ADMIRE-CD II

Conference

DDW 2024

Type

Peer-reviewed article

11 July 2024 12:47

VIVID-1: Mirikizumab meets expectations in Crohn’s disease

Presented By

Prof. Marc Ferrante, University Hospitals Leuven, Belgium

Trial

Phase 3, VIVID-1

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:49

SEQUENCE: Risankizumab versus ustekinumab across endpoints

Presented By

Prof. Marla Dubinsky, Mount Sinai Hospital, NY, USA

Trial

Phase 3, SEQUENCE

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:45

Fatigue, urgency, and QoL improvements on mirikizumab in Crohn’s disease

Presented By

Prof. Simon Travis, University of Oxford, UK

Trial

Phase 3, VIVID-1

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:41

PROFILE: Top-down treatment strategy benefits patients with early Crohn’s disease

Presented By

Dr Nuru Noor, Cambridge University Hospitals, UK

Trial

PROFILE

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:38

Ustekinumab as alternative for anti-TNFs in HLA-DQA1*05-positive Crohn’s disease

Presented By

Dr Jordi Guardiola, University Hospital Bellvitge, Spain

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:33

Promising data for JAK inhibitors in Crohn’s disease from phase 2 trial

Presented By

Dr Séverine Vermeire, University Hospitals Leuven, Belgium

Trial

Phase 2, PIZZICATO

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:28

U-ENDURE long-term extension: sustained efficacy of upadacitinib in Crohn’s disease

Presented By

Dr Geert D’Haens, Amsterdam University Medical Centers, the Netherlands

Trial

U-ENDURE

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:25

CURE-CD: Capsule endoscopy-guided proactive treatment leads to fewer relapses in Crohn’s disease

Presented By

Dr Shomron Ben-Horin, Tel-Aviv University, Israel

Trial

CURE-CD

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:10

Extended mesenterectomy or mesenteric-sparing surgery in Crohn’s disease?

Presented By

Dr Eline van der Does de Willebois, Amsterdam University Medical Centers, the Netherlands

Trial

SPICY

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 12:33

Similar outcomes for Kono-S and side-to-side anastomosis in Crohn’s terminal ileitis

Presented By

Dr Koianka Trencheva, Weill Cornell Medicine, NY, USA

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 12:29

Risk factors for re-resection in Crohn’s disease revealed

Presented By

Dr Anja Poulsen, Copenhagen University, Denmark

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 12:26

ADMIRE-CD-II: Darvadstrocel does not meet primary endpoint in complex peri-anal fistula

Presented By

Dr Zuzana Serclova, Hořovice Hospital, Czech Republic

Trial

Phase 3, ADMIRE-CD-II

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 12:23

DIVERSITY1: Filgotinib results in Crohn’s disease leave investigators puzzled

Presented By

Prof. Séverine Vermeire, UZ Leuven, Belgium

Trial

Phase 3, DESTINY1

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 15:48

SEQUENCE: Risankizumab doubles endoscopic remission rates compared with ustekinumab in CD

Presented By

Prof. Laurent Peyrin-Biroulet, University Hospital of Nancy, France

Trial

Phase 3, SEQUENCE

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 15:44

Risankizumab resolves extraintestinal manifestations in CD

Presented By

Prof. Subrata Ghosh, Cork University College, Ireland

Trial

Phase 3, ADVANCE; MOTIVATE; FORTIFY

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 15:36

Rapid response to upadacitinib boosts outcomes in severe Crohn’s disease

Presented By

Prof. Jean-Frederic Colombel, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 3, U-EXCEED; U-EXCEL

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 15:27

Linking the Black Death with Crohn’s disease predisposition

Expert

Dr Luis Barreiro, University of Chicago, IL, USA

19 July 2023 15:50

EVOLVE Expansion study: vedolizumab and ustekinumab as first-line biologic treatments for Crohn’s disease

Presented By

Prof. Marc Ferrante, KU Leuven, Belgium

Trial

EVOLVE

Conference

DDW 2023

Type

News article

13 June 2023 13:56

Crohn’s disease: Upadacitinib improves endoscopic outcomes in participants with or without previous biologic failure

Presented By

Dr Brian Feagan, Western University, Canada

Trial

Phase 3, U-EXCEL, U-EXCEED, U-ENDURE

Conference

DDW 2023

Type

News article

13 June 2023 13:50

Checking kidney function is important during the course of IBD

Presented By

Dr Yuanhang Yang, Karolinska Institutet, Sweden

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 17:05

Long-term resection potentially better than anti-TNF treatment in CD

Presented By

Prof. Manasi Agrawal, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

LIR!C

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 16:58

Early, post-operative complications in CD reduced by pre-operative enteral nutrition, irrespective of biologic exposure

Presented By

Prof. Mathurin Fumery, Amiens University Hospital, France

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 16:55

Perinatal period is crucial for the risk of developing CD

Presented By

Prof. Sun-Ho Lee, Mount Sinai Hospital, Canada

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 16:53

Early-life antibiotic exposure: a risk factor for paediatric-onset IBD

Presented By

Dr Mikkel Malham, Copenhagen University Hospital, Denmark

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 16:46

Proton pump inhibitors associated with worse outcomes in CD

Presented By

Dr Stéphanie Barrau, Saint Etienne University Hospital, France

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 16:42

Poor sleep in CD linked to low levels of vitamin D

Presented By

Dr Caroline Walker, Tallaght University Hospital, Ireland

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 16:38

Beneficial effect of early, post-operative vedolizumab on endoscopic recurrence in CD

Presented By

Prof. Geert D’Haens , Academic Medical Center University of Amsterdam, the Netherlands

Trial

REPREVIO

Conference

ECCO

Type

Peer-reviewed article

4 May 2023 16:28

Anti-TNF withdrawal may be a safe option in stable IBD

Presented By

Prof. María Chaparro Sánchez , Hospital Universitario de La Princesa, Spain

Trial

Phase 4, EXIT

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 16:12

Intensified drug therapy leads to better stricture morphology in CD

Presented By

Dr Julien Schulberg , St Vincent’s Hospital Melbourne, Australia

Trial

STRIDENT

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 16:03

Upadacitinib successful in the management of both CD and UC

Presented By

Dr Brian Feagan , University of Western Ontario, Canada

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 15:40

Favourable maintenance rates for risankizumab also in delayed responders with CD

Presented By

rof. Geert D’Haens, Amsterdam UMC, the Netherlands

Trial

Phase 3, FORTIFY

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 21:56

Upadacitinib for CD: remarkable efficacy in induction therapy

Presented By

Prof. Julian Panés, Hospital Clínic Barcelona, Spain

Trial

Phase 3, U-EXCEL

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 21:42

Pivotal results of etrolizumab for CD partly disappointing

Presented By

Prof. Séverine Vermeire, University Hospital Leuven, Belgium

Trial

Phase 3, BERGAMOT

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 17:27

Better results for vedolizumab in early CD

Presented By

Prof. Geert D’Haens, Amsterdam UMC, the Netherlands

Trial

Phase 4, LOVE-CD

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 17:19

Some patients with limited CD may benefit from an early surgical intervention

Presented By

Dr Melek Zahra Sarikaya, Sjællands Universitetshospital, Denmark

Trial

LIR!C

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 17:11

Dose-interval of adalimumab might be prolonged in CD patients in stable remission

Presented By

Dr Reinier van Linschoten , Franciscus Gasthuis en Vlietland, the Netherlands

Trial

Phase 4, LADI

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 17:01

Too much hygiene: CD in later life?

Presented By

Dr Williams Turpin, Mount Sinai Hospital and the University of Toronto, Canada

Conference

DDW 2022

Type

News article

14 June 2022 22:18

CD: Induction treatment with upadacitinib successful in clinical and endoscopic ratings

Presented By

Prof. Jean-Frederic Colombel, Mount Sinai Hospital, NY, USA

Trial

Phase 3, U-EXCEED

Conference

DDW 2022

Type

News article

14 June 2022 22:07

Multi-Omic and dietary analysis of Crohn’s disease identifies pathogenetic factors

Presented By

Dr Yael Haberman, Sheba Medical Center, Israel

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 17:27

Novel classification system for perianal fistulising Crohn’s disease

Presented By

Dr Philip Tozer, St Mark’s Hospital and Academic Institute, UK

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 17:26

Early biologic therapy induces larger effect than delayed treatment in Crohn’s disease

Presented By

Prof. Shomron Ben-Horin, Tel-Aviv University, Israel

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 17:21

Segmental colectomy beneficial over total colectomy in Chrohn’s disease

Presented By

Dr Gianluca Pellino, University of Campania Luigi Vanvitelli, Italy

Trial

SCOTCH

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 17:11

Stopping infliximab but not antimetabolites leads to more relapses in Crohn’s disease

Presented By

Prof. Edouard Louis, University Hospital Liège, Belgium

Trial

Phase 4, SPARE

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:55

VEDOKIDS: Vedolizumab seems effective in paediatric IBD

Presented By

Dr Dan Turner, Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, Israel

Trial

VEDOKIDS

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:51

Anti-TNFs versus vedolizumab and ustekinumab in Crohn’s disease

Presented By

Dr Neeraj Narula, McMaster University, Canada

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:46

Subcutaneous infliximab versus subcutaneous vedolizumab in IBD

Presented By

Prof. Laurent Peyrin-Biroulet, Nancy University Hospital, France

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:41

Guselkumab maintenance therapy achieved high efficacy rates in Crohn’s disease

Presented By

Prof. Silvio Danese, Vita-Salute San Raffaele University, Italy

Trial

Phase 2, GALAXI-1

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:21

Risankizumab more efficacious in colonic than in ileal Crohn’s disease

Presented By

Dr Peter Bossuyt, Imelda General Hospital, Belgium

Trial

Phase 3, ADVANCE, MOTIVATE, FORTIFY

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:15

Filgotinib seems promising for perianal fistulising Crohn’s disease

Presented By

Dr Walter Reinisch, Medical University of Vienna, Austria

Trial

Phase 2, DIVERGENCE 2

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:04

ECCO 2022 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ECCO 2022

8 March 2022 10:18

Risankizumab meets primary endpoints in maintenance study for CD patients

Presented By

Prof. Marc Ferrante, University Hospital Leuven, Belgium

Trial

Phase 3, FORTIFY

Conference

UEGW 2021

Type

News article

27 October 2021 10:11

Ustekinumab treat-to-target strategy offers long-term alternative for standard-of-care in CD

Presented By

Prof. Laurent Peyrin-Biroulet, University Hospital of Nancy, France

Trial

Phase 3, STARDUST

Conference

UEGW 2021

Type

News article

27 October 2021 10:09

Serious adverse events put a stop to ASTIClite trial for CD

Presented By

Prof. James Lindsay, Barts and The London School of Medicine, UK

Trial

Phase 3, ASTIClite

Conference

UEGW 2021

Type

News article

27 October 2021 09:48

UEGW 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Trial

FORTIFY, VIBRATO umbrella, SELECTION, LIBERTY EoE TREET

Conference

UEGW 2021

20 October 2021 22:21

ECCO 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ECCO 2021

10 August 2021 08:17

Blood proteins predicting relapse in CD identified

Presented By

Mr Nicolas Pierre, University of Liège, Belgium

Trial

Cohort study, STORI

Conference

ECCO 2021

Type

News article

2 July 2021 23:48

Similar efficacy of ustekinumab and adalimumab for moderate-to-severe CD

Presented By

Dr Peter Irving, Guy’s and St. Thomas’ Hospital, UK

Trial

SEAVUE

Conference

ECCO 2021

Type

News article

2 July 2021 23:45

Extracellular RNA has potential as a non-invasive biomarker in IBD

Presented By

Dr Bram Verstockt , University Hospital Leuven, Belgium

Conference

ECCO 2021

Type

News article

2 July 2021 22:51

Ustekinumab safe and effective in elderly CD patients

Presented By

Dr Diego Casas Deza, Hospital Universitario Miguel Servet

Trial

ENEIDA registry

Conference

ECCO 2021

Type

News article

2 July 2021 22:50

Early clinical remission and response following risankizumab therapy in CD

Presented By

Dr Stefan Schreiber, University Hospital Schleswig-Holstein, Germany

Trial

ADVANCE, MOTIVATE

Conference

ECCO 2021

Type

News article

2 July 2021 21:54

Surgical closure plus anti-TNF outperforms anti-TNF alone for perianal fistula

Presented By

Ms Elise Meima-van Praag , Amsterdam University Medical Centre, the Netherlands

Trial

PISA-II

Conference

ECCO 2021

Type

News article

2 July 2021 21:45

Risk of hospitalisation and surgery linked to IBD biological

Presented By

Dr Camilla Bjørn Jensen, Frederiksberg Hospital

Conference

ECCO 2021

Type

News article

2 July 2021 20:20

Infliximab for IBD may blunt antibody responses to SARS-CoV-2

Journal

Gut

23 March 2021 18:30

Sustained efficacy of mirikizumab in moderate-to-severe Crohn’s disease

Principal Investigator

Prof. Bruce E. Sands, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 2, SERENITY

Conference

UEGW 2020

Type

News article

2 November 2020 12:20

First randomised T2T trial using endoscopy to guide dose escalation

Principal Investigator

Prof. Silvio Danese, Humanitas University, Italy

Trial

Phase 3, STARDUST

Conference

UEGW 2020

Type

News article

2 November 2020 11:00

Resolution of mucosal inflammation has dramatic effect

Presented By

Dr N. Plevris, Western General Hospital, Edinburgh, UK

Trial

Cohort study

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 16:15

Role of immune cells in intestinal fibrosis

Presented By

Dr B. Creyns, Catholic University Leuven, Leuven, Belgium

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 16:04

Association between meat consumption and IBD risk

Presented By

Dr C. Dong, Peking University, Beijing, China

Trial

EPIC-IBD

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 16:01

CD exclusion diet corrects dysbiosis

Presented By

Dr J. van Limbergen , Amsterdam University, The Netherlands

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 15:57

Increased risk of small bowel cancer in IBD

Presented By

Dr J. Axelrad, New York University School of Medicine, New York, USA

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 15:53

Increased incidence of colorectal cancer and death in CD

Presented By

Dr O. Olen, Karolinska Insitutet, Solna, Sweden

Trial

Cohort study

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 15:51

Risk of rectal, anal cancer increased in perianal CD

Presented By

Dr M.D. Wewer, University of Copenhagen, Copenhagen, Denmark

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 15:48

Vedolizumab versus ustekinumab

Presented By

Dr H. Alric & Dr V. Biemans

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 15:28

On the cutting edge of pathology and surgery

Presented By

Prof. P. B. Nunes & Prof. A. Spinelli

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 15:23

Impact of strategies on intestinal resection rate

Presented By

Dr D. Ley, University of Wisconsin–Madison, USA

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 15:16

Early ileocaecal resection in CD patients failing conventional treatment

Presented By

Dr T. Stevens, Amsterdam UMC, the Netherlands

Trial

LIR!C

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 15:11

Biologics before surgery in IBD do not elevate infection risk

Presented By

Dr S. Holubar, Cleveland Clinic, USA

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 15:06

Top-down infliximab superior to step-up in children with CD

Presented By

Dr M. Jongsma, Erasmus MC, the Netherlands

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 14:59

Ustekinumab in CD: a T2T trial

Presented By

Prof. L. Peyrin-Biroulet, CHRU de Nancy, France

Trial

Phase 3, STARDUST

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 14:26

Subcutaneous vedolizumab maintenance therapy in CD

Presented By

Prof. S. Vermeire, University Hospital Leuven, Belgium

Trial

Phase 3, VISIBLE 2

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 14:11

Vedolizumab treatment persistence and safety

Presented By

Dr S. Danese & Dr N.A. Cohen, Humanitas University, Milan, Italy

Trial

GEMINI

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 14:04

Pipeline of IBD drugs

Presented By

Prof. W. Sandborn, University of California San Diego, USA

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 13:55

Open-label extension study of risankizumab: final results

Presented By

Dr M. Ferrante, University Hospitals Leuven, Belgium

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 12:53

Clinical remission after dose escalation of upadacitinib

Presented By

Dr W. Sandborn & Dr S. Vermeire

Trial

Phase 2, CELEST, U-ACHIEVE

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 12:45

Possible new treatment targets in IBD

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 12:39

Multi-omics help describe CD phenotypes

Presented By

Dr B. Verstockt, University Hospital Leuven, Belgium

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 10:46

Impact of biologicals on faecal microbiota

Presented By

C. Caenepeel, KU Leuven, Belgium

Conference

ECCO 2020

14 April 2020 10:20

Practice-changing: infliximab in children with Crohn’s

Trial

TISKids

Conference

UEGW 2019

Type

Peer-reviewed article

23 October 2019 23:42

Ileal microbiota predict recurrence in CD patients after resection

Trial

Cohort study, REMIND

Conference

UEGW 2019

Type

Peer-reviewed article

23 October 2019 21:38

Decreased microvilli length in CD patients

Presented By

Prof. Thaddeus Stappenbeck, Washington School of Medicine at St Louis, Missouri, USA

Trial

Phase 3, UNITI-2

Conference

UEGW 2019

Type

Peer-reviewed article

23 October 2019 20:41

Plant-based foods and Mediterranean diet associated with healthy gut microbiome

Presented By

Laura Bolte, University Medical Center Groningen, the Netherlands

Conference

UEGW 2019

Type

Peer-reviewed article

23 October 2019 19:59

Phase 2 data shows benefit for mirikizumab in CD patients

Presented By

Prof. Bruce Sands, Icahn School of Medicine at Mount Sinai, New York, USA

Conference

UEGW 2019

Type

Peer-reviewed article

23 October 2019 19:42

Topical review

Presented By

Dr Joana Torres & Prof. Stephan Vavricka

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 23:51

HDAC6 inhibition by CKD-506

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 23:18

Complementary and alternative medicine associated with chronic fatigue and lower QoL

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 22:53

Selective oral sphingosine 1-phosphate receptor modulator amiselimod

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 22:21

Vedolizumab: Results from the GEMINI programme

Trial

Phase 3, GEMINI

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 21:59

Crohn’s disease exclusion diet + partial enteral nutrition in paediatric Crohn’s disease

Presented By

Dr Arie Levine, Mount Saint Vincent University, Canada

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 21:56

Pathogenesis

Presented By

Dr Jiangwen Zhang, Dr V. Garlatti

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 20:40

The costs and benefits of biologicals

Presented By

Dr Johan Burisch, Frederiksberg Hospital, Denmark

Trial

Cohort study, Epi-IBD

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 20:34

Ustekinumab as maintenance therapy and with shortened interval

Trial

Phase 3, UNIFI

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 20:11

Early remission of Crohn’s disease prevents progression

Presented By

Dr Thierry Yzet, Amiens University Hospital, France

Trial

CALM

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 20:08

Microbial composition and psychological wellbeing

Presented By

Dr Luc Biedermann, University Hospital Zurich, Switzerland

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 20:03

Immune cells and microbes: a happy marriage?

Presented By

Dr Loris Lopetuso, Catholic University of the Sacred Heart, Italy

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 19:42

Efficacy and safety of biosimilars

Trial

CONNECT-IBD and SPOSIB SB2

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 19:35

Gene expression signature predicts non-response

Trial

ACT1, PURSUIT-SC, PROgECT, PURSUIT-J, UNITI

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 18:48

Infliximab retreatment in luminal Crohn’s disease

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 18:36

OPERA II study: MAdCAM-1 antibody SHP647

Trial

OPERA II

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 18:31

Safety of thiopurine + allopurinol vs thiopurine monotherapy

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 18:16

ZNF133 associated with infliximab response

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 17:50

Upadacitinib: data from U-ACHIEVE and CELEST

Trial

U-ACHIEVE and CELEST

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 17:48

Network analysis of GWAS

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 14:51

Moving towards new therapeutic options

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 14:44

Proactive adalimumab trough measurements

Presented By

Dr Amit Assa, Schneider Children’s Hospital, Israel

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 10:20

Relapse after withdrawal of thiopurines

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 10:13

Glycans as novel immunomodulators in inflammatory bowel disease

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 10:04

Switching to biosimilar bDMARDs is safe and efficacious

Presented By

Prof. Kvien, University of Oslo and Diakonhjemmet Hospital, Norway

Trial

Phase 4, NOR-SWITCH

Conference

EULAR 2018

Type

Peer-reviewed article

24 August 2018 22:46

Quiescent disease, characteristics and biomarker correlations

Trial

REACT, CALM

Conference

ECCO 2018

Type

Peer-reviewed article

28 May 2018 23:54

Enhanced post-operative recovery pathways for IBD patients

Conference

ECCO 2018

Type

Peer-reviewed article

28 May 2018 23:46

Combining new drugs with different mechanisms

Trial

EXPLORER

Conference

ECCO 2018

Type

Peer-reviewed article

28 May 2018 23:31

Long-term risk of advanced neoplasia after colonic low-grade dysplasia in IBD

Conference

ECCO 2018

Type

Peer-reviewed article

28 May 2018 23:13

Vedolizumab in anti-TNF-naïve IBD patients and safety profile

Trial

GEMINI

Conference

ECCO 2018

Type

Peer-reviewed article

28 May 2018 23:04

ILC1 distribution predicts response to ustekinumab

Conference

ECCO 2018

Type

Peer-reviewed article

28 May 2018 22:58

Significant reduction of emergency stoma surgeries for CD

Conference

ECCO 2018

Type

Peer-reviewed article

28 May 2018 21:52

Central role of IL-23 in molecular resistance to anti-TNF therapy

Conference

ECCO 2018

Type

Peer-reviewed article

28 May 2018 21:06

Early and significant effects with upadacitinib induction treatment

Trial

CELEST

Conference

ECCO 2018

Type

Peer-reviewed article

28 May 2018 20:45

Genetic predisposition for gut barrier dysfunction

Conference

ECCO 2018

Type

Peer-reviewed article

28 May 2018 20:15

Vedolizumab induces endoscopic remission and healing in refractory CD

Trial

VERSIFY

Conference

ECCO 2018

Type

Peer-reviewed article

28 May 2018 19:50

SHP647 is efficacious and well-tolerated in CD

Trial

OPERA I, OPERA II, TOSCA

Conference

ECCO 2018

Type

Peer-reviewed article

28 May 2018 18:53

Higher rates of remission and healing with vedolizumab vs TNF antagonist

Conference

ECCO 2018

Type

Peer-reviewed article

28 May 2018 17:57

Comparative effectiveness of vedolizumab and ustekinumab in CD

Conference

ECCO 2018

Type

Peer-reviewed article

28 May 2018 16:01

Diagnostic techniques for IBD: the ECCO-ESGAR Guidelines

Conference

ECCO 2018

Type

Peer-reviewed article

28 May 2018 11:48